TY - JOUR
T1 - The great controversy of obstructive sleep apnea treatment for cardiovascular risk benefit
T2 - advancing the science through expert consensus. An official American Thoracic Society Workshop report
AU - Cohen, Oren
AU - Kundel, Vaishnavi
AU - Barbé, Ferran
AU - Peker, Yüksel
AU - McEvoy, Doug
AU - Sánchez-de-la-Torre, Manuel
AU - Gottlieb, Daniel J.
AU - Douglas Bradley, T.
AU - Suarez-Farinas, Mayte
AU - Zinchuk, Andrey
AU - Azarbarzin, Ali
AU - Malhotra, Atul
AU - Schotland, Helena
AU - Gozal, David
AU - Jelic, Sanja
AU - Ramos, Alberto R.
AU - Martin, Jennifer L.
AU - Pamidi, Sushmita
AU - Johnson, Dayna A.
AU - Mehra, Reena
AU - Somers, Virend K.
AU - Hoyos, Camilla M.
AU - Jackson, Chandra L.
AU - Alcantara, Carmela
AU - Billings, Martha E.
AU - Bhatt, Deepak L.
AU - Patel, Sanjay R.
AU - Redline, Susan
AU - Yaggi, Henry K.
AU - Shah, Neomi A.
AU - American Thoracic Society Assembly on Sleep and Respiratory Neurobiology
PY - 2025/1
Y1 - 2025/1
N2 - The prevalence of obstructive sleep apnea (OSA) is on the rise, driven by various factors, including more sensitive diagnostic criteria, increased awareness, enhanced technology through at-home testing enabling easy and cost-effective diagnosis, and a growing incidence of comorbid conditions such as obesity. Treating symptomatic patients with OSA syndrome to enhance quality of life remains a cornerstone approach. However, there is a lack of consensus regarding treatment to improve cardiovascular disease (CVD) outcomes, particularly in light of overall negative results from several randomized controlled trials indicating no benefit of positive airway pressure therapy on primary and secondary CVD events. These randomized controlled trials were limited by suboptimal positive airway pressure adherence, use of composite CVD outcomes, and limited diversity and generalizability to sleep clinic patients. As such, this workshop assembled clinical experts, as well as researchers in basic and translational science, epidemiology, clinical trials, and population health, to discuss the current state and future research directions to guide personalized therapeutic strategies and future research directions in OSA. There was overall consensus among workshop participants that OSA represents a heterogeneous disease with variable endotypes and phenotypes and heterogeneous responses to treatment. Future research should prioritize using multimodal therapeutic approaches within innovative and adaptive trial designs, focusing on specific subgroups of patients with OSA hypothesized to benefit from a CVD perspective. Future work should also be inclusive of diverse populations and consider the life course of OSA to better comprehend treatment strategies that can address the disproportionate impact of OSA on racially minoritized groups. Furthermore, a more holistic approach to sleep must be adopted to include broader assessments of symptoms, sleep duration, and comorbid sleep and circadian disorders. Finally, it is imperative to establish a sleep research consortium dedicated to collecting raw data and biospecimens categorized by OSA subtypes. This will facilitate mechanistic determinations, foster collaborative research, and help bolster the pipeline of early-career researchers.
AB - The prevalence of obstructive sleep apnea (OSA) is on the rise, driven by various factors, including more sensitive diagnostic criteria, increased awareness, enhanced technology through at-home testing enabling easy and cost-effective diagnosis, and a growing incidence of comorbid conditions such as obesity. Treating symptomatic patients with OSA syndrome to enhance quality of life remains a cornerstone approach. However, there is a lack of consensus regarding treatment to improve cardiovascular disease (CVD) outcomes, particularly in light of overall negative results from several randomized controlled trials indicating no benefit of positive airway pressure therapy on primary and secondary CVD events. These randomized controlled trials were limited by suboptimal positive airway pressure adherence, use of composite CVD outcomes, and limited diversity and generalizability to sleep clinic patients. As such, this workshop assembled clinical experts, as well as researchers in basic and translational science, epidemiology, clinical trials, and population health, to discuss the current state and future research directions to guide personalized therapeutic strategies and future research directions in OSA. There was overall consensus among workshop participants that OSA represents a heterogeneous disease with variable endotypes and phenotypes and heterogeneous responses to treatment. Future research should prioritize using multimodal therapeutic approaches within innovative and adaptive trial designs, focusing on specific subgroups of patients with OSA hypothesized to benefit from a CVD perspective. Future work should also be inclusive of diverse populations and consider the life course of OSA to better comprehend treatment strategies that can address the disproportionate impact of OSA on racially minoritized groups. Furthermore, a more holistic approach to sleep must be adopted to include broader assessments of symptoms, sleep duration, and comorbid sleep and circadian disorders. Finally, it is imperative to establish a sleep research consortium dedicated to collecting raw data and biospecimens categorized by OSA subtypes. This will facilitate mechanistic determinations, foster collaborative research, and help bolster the pipeline of early-career researchers.
KW - cardiovascular disease outcomes
KW - health equity
KW - obstructive sleep apnea
KW - positive airway pressure therapy
UR - http://www.scopus.com/inward/record.url?scp=85214028626&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.202409-981ST
DO - 10.1513/AnnalsATS.202409-981ST
M3 - Article
C2 - 39513996
AN - SCOPUS:85214028626
SN - 2329-6933
VL - 22
SP - 1
EP - 22
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 1
ER -